{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:57:18Z","timestamp":1792814238908,"version":"4.5.0"},"reference-count":176,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The predominant neurodegenerative diseases, Alzheimer\u2019s disease, Parkinson\u2019s disease, dementia with Lewy Bodies, Huntington\u2019s disease, amyotrophic lateral sclerosis, and frontotemporal dementia, are rarely pure diseases but, instead, show a diversity of mixed pathologies. At some level, all of them share a combination of one or more different toxic biomarker proteins: amyloid beta (A\u03b2), phosphorylated Tau (pTau), alpha-synuclein (\u03b1Syn), mutant huntingtin (mHtt), fused in sarcoma, superoxide dismutase 1, and TAR DNA-binding protein 43. These toxic proteins share some common attributes, making them potentially universal and simultaneous targets for therapeutic intervention. First, they all form toxic aggregates prior to taking on their final forms as contributors to plaques, neurofibrillary tangles, Lewy bodies, and other protein deposits. Second, the primary enzyme that directs their aggregation is transglutaminase 2 (TGM2), a brain-localized enzyme involved in neurodegeneration. Third, TGM2 binds to calmodulin, a regulatory event that can increase the activity of this enzyme threefold. Fourth, the most common mixed pathology toxic biomarkers (A\u03b2, pTau, \u03b1Syn, nHtt) also bind calmodulin, which can affect their ability to aggregate. This review examines the potential therapeutic routes opened up by this knowledge. The end goal reveals multiple opportunities that are immediately available for universal therapeutic treatment of the most devastating neurodegenerative diseases facing humankind.<\/jats:p>","DOI":"10.3390\/ijms252413424","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T04:14:52Z","timestamp":1734322492000},"page":"13424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-9044","authenticated-orcid":false,"given":"Danton H.","family":"O\u2019Day","sequence":"first","affiliation":[{"name":"Department of Biology, University of Toronto Mississauga, Mississauga, ON L5L 1C6, Canada"},{"name":"Cell and Systems Biology, University of Toronto, Toronto, ON M5S 3G5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rizzi, L., Rosset, I., and Roriz-Cruz, M. (2014). Global epidemiology of dementia: Alzheimer\u2019s and vascular types. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/908915"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Azam, S., Haque, M.E., Balakrishnan, R., Kim, I.S., and Choi, D.K. (2021). The ageing brain: Molecular and cellular basis of neurodegeneration. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.683459"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: Translating evidence into policy","volume":"19","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ding, C., Wu, Y., Chen, X., Chen, Y., Wu, Z., Lin, Z., Kang, D., Fang, W., and Chen, F. (2022). Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990\u20132019. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.952161"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"04160","DOI":"10.7189\/jogh.13.04160","article-title":"Global, regional, and national burden of neurological disorders in 204 countries and territories worldwide","volume":"13","author":"Huang","year":"2023","journal-title":"J. Glob. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/pn-2023-003988","article-title":"Pathology of neurodegenerative disease for the general neurologist","volume":"24","author":"Cullinane","year":"2024","journal-title":"Pract. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00702-014-1288-x","article-title":"Challenges of multimorbidity of the aging brain: A critical update","volume":"122","author":"Jellinger","year":"2015","journal-title":"J. Neural Transm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/brain\/awad059","article-title":"Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated","volume":"146","author":"Robinson","year":"2023","journal-title":"Brain"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gunes, S., Aizawa, Y., Sugashi, T., Sugimoto, M., and Rodrigues, P.P. (2022). Biomarkers for Alzheimer\u2019s disease in the current state: A narrative review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094962"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Penke, B., Sz\u0171cs, M., and Bog\u00e1r, F. (2020). Oligomerization and conformational change turn monomeric \u03b2-Amyloid and Tau proteins toxic: Their role in Alzheimer\u2019s pathogenesis. Molecules, 25.","DOI":"10.3390\/molecules25071659"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10571-017-0574-1","article-title":"Tau proteins and tauopathies in Alzheimer\u2019s disease","volume":"38","author":"Chong","year":"2018","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3858\/emm.2009.41.9.067","article-title":"Intracellular amyloid beta interacts with SOD1 and impairs the enzymatic activity of SOD1: Implications for the pathogenesis of amyotrophic lateral sclerosis","volume":"41","author":"Yoon","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnmol.2019.00025","article-title":"Molecular mechanisms of TDP-43 misfolding and pathology in Amyotrophic Lateral Sclerosis","volume":"12","author":"Prasad","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Suthar, S.K., and Lee, S.Y. (2023). The role of superoxide dismutase 1 in Amyotrophic Lateral Sclerosis: Identification of signaling pathways, regulators, molecular interaction networks, and biological functions through bioinformatics. Brain Sci., 13.","DOI":"10.3390\/brainsci13010151"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-030-51140-1_12","article-title":"Tau protein and frontotemporal dementias","volume":"1281","author":"Goedert","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bousiges, O., and Blanc, F. (2022). Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126371"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Barron, J.C., Hurley, E.P., and Parsons, M.P. (2021). Huntingtin and the synapse. Front. Cell. Neurosci., 15.","DOI":"10.3389\/fncel.2021.689332"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson\u2019s disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-017-1786-7","article-title":"Co-occurrence of mixed proteinopathies in late-stage Huntington\u2019s disease","volume":"135","author":"Turgeon","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4103\/1673-5374.268971","article-title":"Neurodegenerative diseases as proteinopathies-driven immune disorders","volume":"15","author":"Ciccocioppo","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Candelise, N., Scaricamazza, S., Salvatori, I., Ferri, A., Valle, C., Manganelli, V., Garofalo, T., Sorice, M., and Misasi, R. (2021). Protein aggregation landscape in neurodegenerative diseases: Clinical relevance and future applications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116016"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev-cellbio-100617-062636","article-title":"Intercellular spread of protein aggregates in neurodegenerative disease","volume":"34","author":"Davis","year":"2018","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Xiang, L., Wang, Y., Liu, S., Liu, B., Jin, X., and Cao, X. (2023). Targeting protein aggregates with natural products: An optional strategy for neurodegenerative diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411275"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chen, C., Ding, X., Akram, N., Xue, S., and Luo, S.Z. (2019). Fused in sarcoma: Properties, self-assembly and correlation with neurodegenerative diseases. Molecules, 24.","DOI":"10.3390\/molecules24081622"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1017\/cjn.2022.34","article-title":"Current concepts of mixed pathologies in neurodegenerative diseases","volume":"50","author":"Forrest","year":"2023","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"De Mario, A., Peggion, C., Massimino, M.L., Norante, R.P., Zulian, A., Bertoli, A., and Sorgato, M.C. (2019). The link of the prion protein with Ca2+ metabolism and ROS production, and the possible implication in A\u03b2 toxicity. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184640"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kova\u010d, V., and \u010curin \u0160erbec, V. (2022). Prion protein: The molecule of many forms and faces. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031232"},{"key":"ref_29","unstructured":"Long, S., Benoist, C., and Weidner, W. (2023). World Alzheimer Report 2023: Reducing Dementia Risk: Never Too Early, Never Too Late, Alzheimer\u2019s Disease International."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1152\/physrev.00015.2020","article-title":"The complexity of Alzheimer\u2019s disease: An evolving puzzle","volume":"101","author":"Ferrari","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3389\/fnins.2019.00659","article-title":"Alzheimer disease pathogenesis: Insights from molecular and cellular biology studies of oligomeric A\u03b2 and Tau species","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res. Bull."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.4103\/1673-5374.386406","article-title":"Amyloid-beta and tau protein beyond Alzheimer\u2019s disease","volume":"19","author":"Abyadeh","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40120-018-0104-1","article-title":"A review of dementia with Lewy bodies\u2019 impact, diagnostic criteria and treatment","volume":"7","author":"Capouch","year":"2018","journal-title":"Neurol. Ther."},{"key":"ref_35","first-page":"3","article-title":"Lewy body disease or diseases with Lewy bodies?","volume":"10","author":"Colosimo","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Burtscher","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mcp.2016.11.001","article-title":"Genetics of Parkinson\u2019s disease","volume":"30","author":"Lill","year":"2016","journal-title":"Mol. Cell. Probes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.0285-07.2007","article-title":"Aggregated \u03b1-synuclein mediates dopaminergic neurotoxicity in vivo","volume":"27","author":"Periquet","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_41","first-page":"968","article-title":"Frontotemporal dementia\u2014Features, diagnosis and management","volume":"40","author":"Chan","year":"2011","journal-title":"Aust. Fam. Physician"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","article-title":"Frontotemporal dementia","volume":"35","author":"Olney","year":"2017","journal-title":"Neurol. Clin."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cnur.2019.04.011","article-title":"Understanding frontotemporal disease progression and management strategies","volume":"54","author":"Mulkey","year":"2019","journal-title":"Nurs. Clin. N. Am."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","article-title":"An update on genetic frontotemporal dementia","volume":"266","author":"Greaves","year":"2019","journal-title":"J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1038\/s41380-021-01271-2","article-title":"Clinico-genetic findings in 509 frontotemporal disease patients","volume":"26","author":"Wagner","year":"2021","journal-title":"Mol. Psych."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gifford, A., Praschan, N., Newhouse, A., and Chemali, Z. (2023). Biomarkers in frontotemporal dementia: Current landscape and future directions. Biomark. Neuropsychiatry, 8.","DOI":"10.1016\/j.bionps.2023.100065"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/jnnp-2020-323520","article-title":"Fluid biomarkers in frontotemporal dementia: Past, present and future","volume":"92","author":"Swift","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1074\/jbc.RA118.007222","article-title":"The role of liquid\u2013liquid phase separation in aggregation of the TDP-43 low-complexity domain","volume":"294","author":"Babinchak","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00401-018-1942-8","article-title":"Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology","volume":"137","author":"Nana","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00018-023-04739-2","article-title":"Aggregation-prone TDP-43 sequesters and drives pathological transitions of free nuclear TDP-43","volume":"80","author":"Keating","year":"2023","journal-title":"Cell Mol Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/jnc.12441","article-title":"Transglutaminase 2 accelerates neuroinflammation in amyotrophic lateral sclerosis through interaction with misfolded superoxide dismutase 1","volume":"128","author":"Oono","year":"2014","journal-title":"J. Neurochem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: A clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Abramzon, Y.A., Fratta, P., Traynor, B.J., and Chia, R. (2020). The overlapping genetics of Amyotrophic Lateral Sclerosis and frontotemporal dementia. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00042"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/brain\/awac077","article-title":"Biomarker discovery and development for frontemporal dementia and amyotrophic lateral sclerosis","volume":"145","author":"Katseff","year":"2022","journal-title":"Brain"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"38084","DOI":"10.1074\/jbc.M105296200","article-title":"A Fraction of Yeast Cu,Zn-Superoxide Dismutase and its Metallochaperone, CCS, Localize to the intermembrane space of mitochondria. A ohysiological role for SOD1 in guarding against mitochondrial oxidative damage","volume":"276","author":"Sturtz","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1159\/000111445","article-title":"Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis","volume":"18","author":"Shibata","year":"1996","journal-title":"Dev. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00401-013-1125-6","article-title":"Protein aggregation in amyotrophic lateral sclerosis","volume":"125","author":"Blokhuis","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"E3935","DOI":"10.1073\/pnas.1613854114","article-title":"Spinal motor neuron protein supersaturation patterns are associated with inclusion body formation in ALS","volume":"114","author":"Ciryam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Parobkova, E., and Matej, R. (2021). Amyotrophic Lateral Sclerosis and frontotemporal lobar degenerations: Similarities in genetic background. Diagnostics, 11.","DOI":"10.3390\/diagnostics11030509"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Farrawell, N., Lambert-Smith, I., Warraich, S., Blair, I.P., Saunders, D.N., Hatters, D.M., and Yerbury, J.J. (2015). Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into cellular inclusions. Sci. Rep., 5.","DOI":"10.1038\/srep13416"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Jiang, A., Handley, R.R., Lehnert, K., and Snell, R.G. (2023). From pathogenesis to therapeutics: A review of 150 Years of Huntington\u2019s disease research. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241613021"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41418-021-00914-9","article-title":"The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities","volume":"29","author":"Iennaco","year":"2022","journal-title":"Cell. Death Differ."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Korsten, G., Osinga, M., Pelle, R.A., Serweta, A.K., Hoogenberg, B., Kampinga, H.H., and Kapitein, L.C. (2024). Nuclear poly-glutamine aggregates rupture the nuclear envelope and hinder its repair. J. Cell Biol., 223.","DOI":"10.1083\/jcb.202307142"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JPD-230154","article-title":"Prevalence of concomitant pathologies in Parkinson\u2019s disease: Implications for prognosis, diagnosis, and Insights into common pathogenic mechanisms","volume":"14","author":"Walker","year":"2024","journal-title":"J Parkinsons Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41531-023-00494-0","article-title":"A scoping review of neurodegenerative manifestations in explainable digital phenotyping","volume":"9","author":"Alfalahi","year":"2023","journal-title":"npj Parkinsons Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/B978-0-323-85538-9.00012-2","article-title":"Mixed pathology as a rule, not exception: Time to reconsider disease nosology","volume":"192","author":"Chu","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awaa438","article-title":"The development and convergence of co-pathologies in Alzheimer\u2019s disease","volume":"144","author":"Robinson","year":"2021","journal-title":"Brain"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jamaneurol.2020.1741","article-title":"Prevalence and clinical phenotype of quadruple misfolded proteins in older adults","volume":"77","author":"Karanth","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1007\/s00415-020-09718-2","article-title":"TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional\/diffuse Lewy body disease","volume":"267","author":"Buciuc","year":"2020","journal-title":"J. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5114\/fn.2021.111486","article-title":"Mixed pathologies mimicking motor neuron disease: A case report and review of the literature","volume":"59","author":"Dey","year":"2021","journal-title":"Folia Neuropathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2015.0606","article-title":"Clinical features of Alzheimer disease with and without Lewy bodies","volume":"7","author":"Chung","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_74","unstructured":"Haider, A., Spurling, B.C., and S\u00e1nchez-Manso, J.C. (2024). Lewy Body Dementia. StatPearls [Internet], StatPearls Publishing. Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482441\/."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1821","DOI":"10.1212\/WNL.0000000000007315","article-title":"Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies","volume":"92","author":"Buchman","year":"2019","journal-title":"Neurology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Han, Y., and He, Z. (2023). Concomitant protein pathogenesis in Parkinson\u2019s disease and perspective mechanisms. Front. Aging Neurosci., 15.","DOI":"10.3389\/fnagi.2023.1189809"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","article-title":"Synergistic interactions between A\u03b2, Tau, and a-synuclein: Acceleration of neuropathology and cognitive decline","volume":"30","author":"Clinton","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Yang, J., Hamade, M., Wu, Q., Wang, Q., Axtell, R., Giri, S., and Mao-Draayer, Y. (2022). Current and future biomarkers in multiple sclerosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23115877"},{"key":"ref_79","first-page":"699","article-title":"Biomarkers for amyotrophic lateral sclerosis","volume":"35","author":"Witzel","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: A retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1134\/S0026893320010136","article-title":"[Genetic diversity in frontotemporal dementia]","volume":"54","author":"Shpilyukova","year":"2020","journal-title":"Mol. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/17482968.2012.678365","article-title":"Combined fulminant frontotemporal dementia and amyotrophic lateral sclerosis associated with an I113T SOD1 mutation","volume":"13","author":"Katz","year":"2012","journal-title":"Amyotroph. Lateral Scler."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00401-015-1442-z","article-title":"Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: Frontotemporal lobar degeneration associated with \u03b1-synuclein","volume":"130","author":"Aoki","year":"2015","journal-title":"Acta Neuropathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-230569","article-title":"Implications of Tau dysregulation in Huntington\u2019s disease and potential for new therapeutics","volume":"12","author":"Mees","year":"2023","journal-title":"J. Huntingtons Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ch\u00e1nez-C\u00e1rdenas, M.E., and V\u00e1zquez-Contreras, E. (2012). The aggregation of huntingtin and \u03b1-Synuclein. J. Biophys., 2012.","DOI":"10.1155\/2012\/606172"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0306-4522(00)00391-2","article-title":"Amyloid-like inclusions in Huntington\u2019s disease","volume":"100","author":"McGowan","year":"2000","journal-title":"Neuroscience"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/jnnp.2005.084673","article-title":"Selective reduction of amyloid beta42 discriminates Alzheimer\u2019s disease from Huntington\u2019s disease: Indication for distinct pathological events in amyloid beta peptide aggregation","volume":"77","author":"Mollenhauer","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1994.tb44398.x","article-title":"Calcium hypothesis of Alzheimer\u2019s disease and brain aging","volume":"747","author":"Khachaturian","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00424-009-0736-1","article-title":"Calcium hypothesis of Alzheimer\u2019s disease","volume":"459","author":"Berridge","year":"2010","journal-title":"Pfluger\u2019s Arch."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association Calcium Hypothesis Workgroup (2017). Calcium hypothesis of Alzheimer\u2019s disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. Alz. Dement., 13, 178\u2013182.","DOI":"10.1016\/j.jalz.2016.12.006"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.3390\/cimb45080393","article-title":"Alzheimer\u2019s disease beyond calcium dysregulation: The complex interplay between calmodulin, calmodulin binding proteins and amyloid beta from disease onset through progression","volume":"45","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00018-013-1550-7","article-title":"Neuronal calcium signaling: Function and dysfunction","volume":"71","author":"Brini","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0962-8924(00)01800-6","article-title":"R Calmodulin: A prototypical calcium sensor","volume":"10","author":"Chin","year":"2000","journal-title":"Trends Cell. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Pepke, S., Kinzer-Ursem, T., Mihala, S., and Kennedy, M.B. (2010). A dynamic model of interactions of Ca2+.; calmodulin.; and catalytic subunits of Ca2+\/calmodulin-dependent protein kinase II. PLoS Comput. Biol., 6.","DOI":"10.1371\/journal.pcbi.1000675"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"O\u2019Day, D.H., and Huber, R.L. (2022). Calmodulin binding proteins and neuroinflammation in multiple neurodegenerative diseases. BMC Neurosci., 23.","DOI":"10.1186\/s12868-022-00695-y"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bbrc.2016.09.053","article-title":"Dysregulation of neuronal calcium homeostasis in Alzheimer\u2019s disease\u2014A therapeutic opportunity?","volume":"483","author":"Popugaeva","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_98","first-page":"1","article-title":"Cytosolic calcium: Judge jury and executioner of neurodegeneration in Alzheimer\u2019s disease and beyond","volume":"19","author":"Webber","year":"2023","journal-title":"Alz. Dementia"},{"key":"ref_99","first-page":"1051","article-title":"Calmodulin-binding domains in Alzheimer\u2019s disease proteins: Extending the calcium hypothesis","volume":"230","author":"Myre","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JAD-142772","article-title":"Calmodulin Binding Proteins and Alzheimer\u2019s Disease: A Review","volume":"46","author":"Eshak","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"O\u2019Day, D.H. (2024). The complex interplay between toxic hallmark proteins, calmodulin-binding proteins, ion channels, and receptors involved in calcium dyshomeostasis in neurodegeneration. Biomolecules, 14.","DOI":"10.3390\/biom14020173"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4161\/pri.23581","article-title":"Neuronal Ca(2+) dyshomeostasis in Huntington disease","volume":"7","author":"Giacomello","year":"2013","journal-title":"Prion"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.32607\/20758251-2017-9-2-34-46","article-title":"Huntington\u2019s disease: Calcium dyshomeostasis and pathology models","volume":"9","author":"Kolobkova","year":"2017","journal-title":"Acta Naturae"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/fnl.09.17","article-title":"Transglutaminase activation in neurodegenerative diseases","volume":"4","author":"Jeitner","year":"2009","journal-title":"Future Neurol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0896-6273(03)00366-0","article-title":"Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1","volume":"39","author":"Tang","year":"2003","journal-title":"Neuron"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1093\/hmg\/ddu112","article-title":"Over expression of the calpain-specific inhibitor calpastatin reduces human alpha-synuclein processing, aggregation and synaptic impairment in [A30P] \u03b1Syn transgenic mice","volume":"23","author":"Diepenbroek","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1242\/dmm.028738","article-title":"The role of Ca2+ signaling in Parkinson\u2019s disease","volume":"10","author":"Zalchick","year":"2017","journal-title":"Dis. Mod. Mech."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbrc.2016.08.168","article-title":"Calcium and Parkinson\u2019s disease","volume":"483","author":"Surmeier","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1073\/pnas.0438021100","article-title":"Tissue transglutaminase-induced aggregation of alpha synuclein: Implications for Lewy body formation in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"100","author":"Junn","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.mcn.2010.12.004","article-title":"Raised calcium promotes \u03b1-synuclein aggregate formation","volume":"46","author":"Nath","year":"2011","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Leandrou, E., Emmanouilidou, E., and Vekrellis, K. (2019). Voltage-gated calcium channels and \u03b1-Synuclein: Implications in Parkinson\u2019s disease. Front. Mol. Neurosci., 12.","DOI":"10.3389\/fnmol.2019.00237"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Costas-Ferreira, C., and Faro, L.R.F. (2021). Systematic review of calcium channels and intracellular calcium signaling: Relevance to pesticide neurotoxicity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413376"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1038\/s41467-023-38215-z","article-title":"A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides","volume":"14","author":"Paul","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Bohush, A., Le\u015bniak, W., Weis, S., and Filipek, A. (2021). Calmodulin and its binding proteins in Parkinson\u2019s disease. Int. J. Mol. Med., 22.","DOI":"10.3390\/ijms22063016"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"O\u2019Day, D.H. (2020). Calmodulin binding proteins and Alzheimer\u2019s disease: Biomarkers.; regulatory enzymes and receptors that are regulated by calmodulin. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197344"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4161\/pri.23582","article-title":"The pathology roadmap in Parkinson disease","volume":"7","author":"Surmeier","year":"2013","journal-title":"Prion"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12272-021-01334-6","article-title":"Complicity of \u03b1-synuclein oligomer and calcium dyshomeostasis in selective neuronal vulnerability in lewy body disease","volume":"44","author":"Yamamoto","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","article-title":"Different species of alpha-synuclein oligomers induce calcium influx and seeding","volume":"27","author":"Danzer","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1080\/14660820152415744","article-title":"Calcium: The Darth Vader of ALS","volume":"2","author":"Appel","year":"2001","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ana.410360608","article-title":"The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis","volume":"36","author":"Alexianu","year":"1994","journal-title":"Ann. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ceca.2009.12.002","article-title":"Calcium dysregulation in amyotrophic lateral sclerosis","volume":"47","author":"Grosskreutz","year":"2010","journal-title":"Cell Calcium"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"De Marco, G., Lomartire, A., Manera, U., Canosa, A., Grassano, M., Casale, F., Fuda, G., Salamone, P., Rinaudo, M.T., and Colombatto, S. (2022). Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. Sci. Rep., 12.","DOI":"10.1038\/s41598-021-04267-8"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/exnr.1999.7190","article-title":"ALS-linked Cu\/Zn-SOD1 mutation increases vulnerability of motor neurons to excitotocity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis","volume":"160","author":"Kruman","year":"1999","journal-title":"Exp. Neurol."},{"key":"ref_125","first-page":"I17","article-title":"Molecular factors underlying selective vulnerability of motor neurons to neuro degeneration in amyotrophic lateral sclerosis","volume":"247","author":"Shaw","year":"2000","journal-title":"J. Neuol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/emm.2007.63","article-title":"Calcium-influx increases SOD1 aggregates via nitric oxide in cultured motor neurons","volume":"39","author":"Kim","year":"2007","journal-title":"Exp. Mol. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Katzeff, J.S., Bright, F., Lo, K., Kril, J.J., Connolly, A., Crossett, B., Ittner, L.M., Kassiou, M., Loy, C.T., and Hodges, J.R. (2020). Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-70687-7"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Phan, K., He, Y., Pickford, R., Bhatia, S., Katzeff, J.S., Hodges, J.R., Piguet, O., Halliday, G.M., and Kim, W.S. (2020). Uncovering pathophysiological changes in frontotemporal dementia using serum lipids. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-60457-w"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Savoca, M., Tonoli, E., Atobatele, A., and Verderio, E. (2018). Biocatalysis by transglutaminases: A review of biotechnological applications. Micromachines, 9.","DOI":"10.3390\/mi9110562"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Duarte, L., Matte, C.R., Bizarro, C.V., and Ayub, M.A.Z. (2019). Review transglutaminases: Part II-industrial applications in food, biotechnology, textiles and leather products. World J. Microbiol. Biotechnol., 36.","DOI":"10.1007\/s11274-019-2792-9"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Tatsukawa, H., and Hitomi, K. (2021). Role of transglutaminase 2 in cell death, survival, and fibrosis. Cells, 10.","DOI":"10.3390\/cells10071842"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Pinkas, D.M., Strop, P., Brunger, A.T., and Khosla, C. (2007). Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol., 5.","DOI":"10.1371\/journal.pbio.0050327"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbamcr.2011.09.012","article-title":"Transglutaminase 2: A molecular Swiss army knife","volume":"1923","author":"Gundemir","year":"2012","journal-title":"Bioch. Biophys. Acta"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Kim, G.E., and Park, H.H. (2020). Structures of human transglutaminase 2: Finding clues for interference in cross-linking mediated activity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062225"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1016\/S0006-3495(00)76860-3","article-title":"Ligand-induced conformational changes in tissue transglutaminase: Monte Carlo analysis of small-angle scattering data","volume":"78","author":"Mariani","year":"2000","journal-title":"Biophys. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1111\/j.1742-4658.2011.08345.x","article-title":"Protein transamidation by transglutaminase 2 in cells: A disputed Ca2+-dependent action of a multifunctional protein","volume":"278","author":"Kiraly","year":"2011","journal-title":"FEBS J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"21978","DOI":"10.1021\/acsomega.2c02502","article-title":"Naturally occurring epsilon gamma glutamyl lysine isopeptide crosslinks in human neuroblastoma SH-SY5Y cells","volume":"7","author":"Lockridge","year":"2022","journal-title":"ACS Omega"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0006-8993(94)90688-2","article-title":"Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide","volume":"651","author":"Dudek","year":"1994","journal-title":"Brain Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1523\/JNEUROSCI.4424-03.2004","article-title":"Calmodulin regulates transglutamase 2 cross-linking of huntingtin","volume":"24","author":"Zainelli","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_140","first-page":"5","article-title":"Tissue transglutaminase, protein cross-linking and Alzheimer\u2019s disease: Review and views","volume":"1","author":"Wang","year":"2008","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Liu, J., and Mouradian, M.M. (2024). Pathogenetic contributions and therapeutic implications of transglutaminase 2 in neurodegenerative diseases. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042364"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Szondy, Z., Korponay-Szabo, I., Kiraly, R., Sarang, Z., and Tsay, G.J. (2017). Transglutaminase 2 in human diseases. Biomedicine, 7.","DOI":"10.1051\/bmdcn\/2017070315"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5483\/BMBRep.2018.51.1.227","article-title":"New insight into transglutamase 2 and link to neurodegenerative diseases","volume":"51","author":"Min","year":"2018","journal-title":"BMB Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1523\/JNEUROSCI.3263-04.2005","article-title":"Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice","volume":"25","author":"Halverson","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Panes-Fernandez, J., Godoy, P.A., Gavilan, J., Ramirez-Molina, O., Burgos, C.F., Marileo, A., Flores-Nunez, O., Castro, P.A., Moraga-Cid, G., and Yevenes, G.E. (2023). TG2 promotes amyloid beta aggregates: Impact on ER-mitochondria crosstalk, calcium homeostasis and synaptic function in Alzheimer\u2019s disease. Biomed. Pharmacother., 162.","DOI":"10.1016\/j.biopha.2023.114596"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Muschol, M., and Hoyer, W. (2023). Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1120416"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1750-3639.2008.00197.x","article-title":"Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer\u2019s disease brain","volume":"19","author":"Wilhelmus","year":"2009","journal-title":"Brain Pathol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Wilhelmus, M.M.M., Jongenelen, C.A., Bol, J.G.J.M., and Drukarch, B. (2020). Interaction between tissue transglutaminase and amyloid-beta: Protein-protein binding versus enzymatic crosslinking. Anal. Biochem., 592.","DOI":"10.1016\/j.ab.2020.113578"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnen\/62.1.14","article-title":"Transglutaminase cross-links in intranuclear inclusions in Huntington disease","volume":"62","author":"Zainelli","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_150","first-page":"58","article-title":"Mutant huntingtin protein, a substrate for transglutaminase 1, 2, and 3. J. Neuropathol","volume":"64","author":"Zainelli","year":"2005","journal-title":"Exp. Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1046\/j.1471-4159.1999.02018.x","article-title":"Tissue transglutamase is increased in Huntington\u2019s disease brain","volume":"73","author":"Lesort","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1016\/S0021-9258(17)36359-7","article-title":"Catalytic properties of a calmodulin-regulated transglutaminase from human platelet and chicken gizzard","volume":"260","author":"Puszkin","year":"1985","journal-title":"J. Biol. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.tips.2014.10.014","article-title":"Inhibitors of tissue transglutaminase","volume":"36","author":"Keillor","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1096\/fj.03-0829fje","article-title":"Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson\u2019s disease","volume":"18","author":"Andringa","year":"2004","journal-title":"FASEB J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/jnr.21352","article-title":"Enhanced accumulation of phosphorylated \u03b1-synuclein in double transgenic mice expressing mutant \u03b2-amyloid precursor protein and presenilin-1","volume":"85","author":"Kurata","year":"2007","journal-title":"J. Neuro. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-510X(98)00088-4","article-title":"Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: A possible use as an indicator of extent of the motor neuron loss","volume":"158","author":"Fujita","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Salzinger, A., Ramesh, V., Das Sharma, S., Chandran, S., and Thangaraj Selvaraj, B. (2024). Neuronal circuit dysfunction in Amyotrophic Lateral Sclerosis. Cells, 13.","DOI":"10.3390\/cells13100792"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Paul, B.D., and Snyder, S.H. (2019). Therapeutic applications of cysteamine and cystamine in neurodegenerative and neuropsychiatric diseases. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01315"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"O\u2019Day, D.H. (2023). Calmodulin and amyloid beta as coregulators of critical events during the onset and progression of Alzheimer\u2019s disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021393"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.3390\/cimb44110394","article-title":"Calmodulin binding domains in critical risk proteins involved in neurodegeneration","volume":"44","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.bbrc.2017.03.151","article-title":"High affinity binding of amyloid b-peptide to calmodulin: Structural and functional implications","volume":"486","author":"Corbacho","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00231699","article-title":"Calmodulin binds to a tubulin binding site of the microtubule associated protein tau","volume":"97","author":"Padilla","year":"1990","journal-title":"Mol. Cell. Biochem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"a006247","DOI":"10.1101\/cshperspect.a006247","article-title":"Biochemistry and cell biology of tau protein in neurofibrillary degeneration","volume":"2","author":"Mandelkow","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"17379","DOI":"10.1074\/jbc.M209020200","article-title":"Parkinson\u2019s disease-associated \u03b1-synuclein is a calmodulin substrate","volume":"278","author":"Martinez","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1073\/pnas.93.10.5037","article-title":"Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin","volume":"93","author":"Bao","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.drudis.2018.01.037","article-title":"The diamond anniversary of tissue transglutaminase: A protein of many talents","volume":"23","author":"Katt","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/kinasesphosphatases2010005","article-title":"Transglutaminase2: An Enduring Enzyme in Diabetes and Age-Related Metabolic Diseases","volume":"2","author":"Yadav","year":"2024","journal-title":"Kinases Phosphatases"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.05.003","article-title":"Transglutaminase 2 inhibitors and their therapeutic role in disease states","volume":"115","author":"Siegel","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14728222.2021.1989410","article-title":"Transglutaminase 2 as a therapeutic target for neurological conditions","volume":"25","author":"Keillor","year":"2021","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JHD-180312","article-title":"Cysteamine Protects Neurons from Mutant Huntingtin Toxicity","volume":"8","author":"Arbez","year":"2019","journal-title":"J. Huntingt. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41417-023-00641-y","article-title":"Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target","volume":"30","author":"Malkomes","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1021\/acschemneuro.2c00305","article-title":"Small-molecule disruptors of mutant Huntingtin\u2013calmodulin protein\u2013protein interaction attenuate deleterious effects of mutant huntingtin","volume":"13","author":"Kapadia","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Baltasar-Marchueta, M., Llona, L., M-Alicante, S., Barbolla, I., Ibarluzea, M.G., Ramis, R., Salomon, A.M., Fundora, B., Araujo, A., and Muguruza-Montero, A. (2024). Identification of Riluzole derivatives as novel calmodulin inhibitors with neuroprotective activity by a joint synthesis, biosensor, and computational guided strategy. Biomed. Pharmacother., 174.","DOI":"10.1016\/j.biopha.2024.116602"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"101273","DOI":"10.1016\/j.arr.2021.101273","article-title":"Demonstrated hormetic mechanisms putatively subserve riluzole-induced effects in neuroprotection against amyotrophic lateral sclerosis (ALS): Implications for research and clinical practice","volume":"67","author":"Calabrese","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbadis.2012.06.003","article-title":"Higher susceptibility to amyloid fibril formation of the recombinant ovine prion protein modified by transglutaminase","volume":"1822","author":"Sorrentino","year":"2012","journal-title":"Biochim. Biophys. Acta"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:31Z","timestamp":1760115331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/24\/13424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":176,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252413424"],"URL":"https:\/\/doi.org\/10.3390\/ijms252413424","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]}}}